Showing results (11-20 of 272) with videos related to

Sort By:
Pageof 28
Cancer Investigation|October 14, 2015
Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical TrialsJamie Pawlowski, Laeeq Malik, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology|May 16, 2024
Emerging targeted therapies and strategies to overcome resistance in biliary tract cancersTarik Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers|March 13, 2025
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal AdenocarcinomaTarik Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers|August 3, 2019
Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC)Pedro Viveiros, Ahsun Riaz, Robert J Lewandowski, et al.
Leukemia & Lymphoma|June 10, 2010
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agentsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Cancer Treatment Reviews|January 2, 2009
TRAIL receptor signalling and modulation: Are we on the right TRAIL?Devalingam Mahalingam, Eva Szegezdi, Maccon Keane, et al.
Targeted Oncology|April 22, 2009
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitorsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Targeted Oncology|May 5, 2011
Clinical activity of mammalian target of rapamycin inhibitors in solid tumorsYesid Alvarado, Monica M Mita, Sushma Vemulapalli, et al.
Journal of Gastrointestinal Cancer|April 23, 2017
Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?Sukeshi Patel Arora, Norma S Ketchum, Joel Michalek, et al.
Future Oncology (London, England)|April 21, 2009
Targeting the mTOR pathway using deforolimus in cancer therapyDevalingam Mahalingam, Kamalesh Sankhala, Alain Mita, et al.
Pageof 28